Clinical trials: Severe Ischaemic Stroke
Multimorbidity, Hypertension
Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity
This study aims to test a new comprehensive management service package for older adults with two or more chronic conditions (multimorbidity).
- Conditions
- Multimorbidity, Hypertension, Diabetes Mellitus, Coronary Artery Disease
- Trial name
- COMPASS (NCT07151430)
- Testing
- Service Package Group
- Volunteers
- 358 people
- Sponsor
- Xuanwu Hospital, Beijing
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Acute Ischaemic Stroke
Pragmatic Ischaemic Stroke Thrombectomy Evaluation
Ischaemic strokes (those caused by blockage in an artery in the brain caused by a blood clot) can be treated with very early use of clot-busting (thrombolytic) drugs to attempt to restore the blood supply and limit the damage…
- Trial name
- PISTE (NCT01745692)
- Testing
- Mechanical thrombectomy, Intravenous rtPA
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- NHS Greater Glasgow and Clyde
Small Vessel Cerebrovascular Disease, Stroke
Intensive Blood Pressure Control in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease
Objectives: Cerebral small vessel disease (SVD) is a common disease in patients with ischemic stroke and the most common cause of vascular dementia. Blood pressure (BP)-lowering is generally considered neuroprotective.
- Trial name
- NCT05690997
- Testing
- Intensive treatment, Standard treatment
- Where
- Hong Kong
- Volunteers
- 104 people
- Sponsor
- The University of Hong Kong
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Stroke
Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls
The investigators expect to find higher levels of both classical and minor antiphospholipid (APL) antibodies among the stroke cases. Furthermore, the investigators expect to find not only classical APLA but also minor antibodies.
- Trial name
- NCT01487746
- Where
- Israel
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Ischemic Stroke
Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis
To observe the safety and efficacy of intensive drug therapy for ischemic stroke caused by severe intracranial arterial stenosis.Patients with acute stroke caused by intracranial arterial stenosis (stenosis rate ≥70%) were…
- Trial name
- NCT05996978
- Testing
- Intensive Drug Therapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Ischemic Stroke, Acute
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
The aim of this study was to evaluate the efficacy and safety of Minocycline versus placebo in the treatment of patients with moderate to severe acute ischemic stroke.
- Trial name
- EMPHASIS (NCT05836740)
- Testing
- Minocycline hydrochloride capsule
- Where
- 58 sites in China
- Volunteers
- 1,724 people
- Sponsor
- Beijing Tiantan Hospital
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Protective Effect of EPA on Cardiovascular Events
The purpose of this study was to test the hypothesis that the long-term use of highly (>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing…
- Trial name
- NCT00231738
- Testing
- Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
- Where
- Japan
- Volunteers
- 18,000 people
- Sponsor
- Kobe University
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Cardiovascular Disease, Dementia
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults.
- Trial name
- DAN-ZOSTER (NCT07485283)
- Testing
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Where
- 2 sites in Denmark
- Volunteers
- 168,460 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Acute Ischemic Stroke, Stroke, Acute
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the daily living ability of acute ischemic stroke at 90 days.
- Conditions
- Acute Ischemic Stroke, Stroke, Acute, Stroke, Ischemic
- Trial name
- XMAS-2 (NCT04150835)
- Testing
- Xingnaojing injection, Standard care
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Dongzhimen Hospital, Beijing
Coronary Artery Disease, Chest Pain
Artificial Intelligence Stress Echo (FINESSE) Project
The goal of this observational study is to learn whether combining stress echocardiography (stress echo) results with routine clinical information can better predict important heart outcomes in adults (18+) with chest pain who…
- Conditions
- Coronary Artery Disease, Chest Pain, Myocardial Ischemia, Angina Pectoris
- Trial name
- FINESSE (NCT07432620)
- Testing
- Dobutamine Stress Echocardiography
- Where
- United Kingdom
- Volunteers
- 2,281 people
- Sponsor
- Milton Keynes University Hospital NHS Foundation Trust
Acute Ischemic Stroke
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Severe Stenosis or Occlusion of Anterior Intracranial Circulation Vessels
The primary purpose of this study is to examine whether remote ischemic treatment can better the 90 - day neurological outcomes in acute ischemic stroke patients having severe stenosis or occlusion of anterior intracranial…
- Trial name
- RICASO (NCT06823128)
- Testing
- RIC, Guideline-based therapy
- Where
- China
- Volunteers
- 458 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Thrombosis, Stent Thrombosis
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of…
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction
- Trial name
- CARES2 (NCT04702113)
- Testing
- Cipherome Lighthouse Pilot
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cipherome, Inc.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Stroke Associated Pneumonia, Non Severe Ischemic Stroke
Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy
Select 50 non-severe ischemic SAP patients with swallowing difficulties in our intensive care unit and randomly divide them into two group.The control group was given conventional anti-infective drugs, expectorants, and…
- Conditions
- Stroke Associated Pneumonia, Non Severe Ischemic Stroke, Dysphagia
- Trial name
- Sottopdaspwb (NCT07345078)
- Testing
- Tracheoscopy suction and bronchoalveolar lavage
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First People's Hospital of Zunyi
COVID-19
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with…
- Trial name
- COVID-PREVENT (NCT04416048)
- Testing
- Rivaroxaban, Standard Of Care (SOC)
- Where
- 24 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Charite University, Berlin, Germany
Acute Ischemic Stroke
Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)
The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.
- Trial name
- XMAS (NCT02728180)
- Testing
- Xingnaojing injection, Standard care
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Dongzhimen Hospital, Beijing
Stroke, Stroke, Acute
Impact of COVID-19 Vaccines on Cerebrovascular Health
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Dementia
- Trial name
- NCT04992195
- Testing
- Laboratory tests and Montreal Cognitive Assessment
- Where
- Hong Kong
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong